Ann: Imugene doses first combination patient in PD1-Vaxx trial, page-26

Fantastic news out of Imugene today.

This is an outstanding announcement for five reasons:

1. PD1 Vaxx was extremely successful in its Phase 1 Trial administered to patients with lung cancer. A complete response and a number of partial responses resulted from the small cohorts of patients in the trial.

2. PD1 Vaxx is combining with a drug Tercentriq which is successful in its own right and approved by the FDA for a number of indications.

3. Lung cancer accounts for approximately 12% of cancer diagnosis and 21% of all cancer deaths. Unfortunately this an area of huge unmet need worldwide, particularly throughout Asia

4. PD1 Vaxx is patented extensively throughout Asia, Europe and the US by Imugene, and

5. Significantly Imugene is partnering with Roche, a large Big Pharma with strong ties to Imugene's CEO Leslie Chong, Dr Jakob Dupont and business leader Monil Shah. it goes without saying Imugene and Roche are now formally in bed together, as a direct consequence of this trial and the subsequent supply agreement between the two organisations.

PD1 Vaxx is a vaccine with enormous potential. Professor Kaumaya has developed a drug that stimulates the immune system to fight off cancer without any side effects, and that can only enhance existing drugs in the marketplace. These drugs include blockbusters such as Keytruda and Opdivo, who despite selling billions of dollars worth of product into this marketplace, bring with them extensive side effects. Added to which PD1 Vaxx has a long patent runway through to 2036 and 2037, providing Big Pharma with years and years of potentate sales revenue.

The ASX may well treat this announcement lightly, but I am confident Asian governments, bio Pharma players and investors in Asia and across the globe are watching closely.


DYOR Seek Investment advice as and when required Opinions only